Diprosone topical cream 0.05%, 30 gm

Available at Pharmaegy Pharmacy. Use as directed by your doctor.

Diprosone Cream 0,05% 30 gm Composition: Each one gram contains: Active ingredient: Betamethasone Dipropionate micronized 0.64 mg (Equivalent to 0.5 mg Betamethasone) Excipients: Chlorocresol, Monosodium phosphate dihydrate, Phosphoric acid (concentrated), Petrolatum, Mineral oil, Cetomacrogol 1000, Cetostearyl alcohol, Purified water Indications: Betamethasone Dipropionate is a synthetic fluorinated corticosteroid. It is active topically and produces a rapid and sustained response in eczema and dermatitis of all types, including atopic eczema, photodermatitis., lichen planus, lichen simplex, prurigo nodularis, discoid lupus erythematosus, necrobiosis lipoidica, pretibial myxodemea and erythroderma. It is also effective in the less responsive conditions such as psoriasis of the scalp and chronic plaque psoriasis of the hands and feet, but excluding widespread plaque psoriasis. Dosage: Adults and Children: Once to twice daily. In most cases a thin film of Diprosone Cream should be applied to cover the affected area twice daily. For some patients adequate maintenance therapy may be achieved with less frequent application. Diprosone Cream is especially appropriate for moist or weeping surfaces and the ointment for dry, lichenifield or scaly lesions but this is not invariably so. Contraindications: -Rosacea, acne, perioral dermatitis, perianal and genital pruritus. -Hypersensitivity to any of the ingredients of the Diprosone presentations contra-indicates their use as does tuberculous and most viral lesions of the skin, particularly herpes simplex, vacinia, varicella. -Diprosone should not be used in napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy. Side Effects: Diprosone skin preparations are generally well tolerated and side-effects are rare. The following local adverse reactions that have been reported with the use of Diprosone include: burning, itching, irritation, dryness, follicultis, hypertrichosis. acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, stride and miliaria. Continuous application without interruption may result in local atrophy of the skin, stride and superficial vascular dilation, particularly on the face. Vision blurred has been reported with corticosteroid use (frequency not known). Precautions: -Local and systemic toxicity is common, especially following long continuous use on large areas of damaged skin, in flexures or with polythene occlusion. If used in children or on the face courses should be limited to 5 days. -Long term continuous therapy should be avoided in all patients irrespective of age. -Occlusion must not be used. -Topical corticosteroids may be hazardous in psoriasis for a number of reasons, including rebound relapses following development of tolerance, risk of generalised pustular psoriasis and local systemic toxicity due to impaired barrier function of the skin. Careful patient supervision is important. -Paediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. -If irritation develops, treatment should be discontinued and appropriate therapy instituted. -Diprosone is not for ophthalmic use. -Visual disturbance may be reported with systemic and topical (including, intranasal, inhaled and intraocular) corticosteroid use. Pregnancy: Topical steroids should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Lactation: Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue the drug, taking into account the importance of the drug to the mother. Storage Method: Store at a temperature not exceeding 30°C. Package: Carton box containing aluminum tube containing 30 gm cream + Insert leaflet.